T cells expressing a chimeric antigen receptor
US12161668B2 · kind B2 · utility
0Cited by
2References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 10, 2018 |
| Grant date | Dec 10, 2024 |
| Priority date | — |
| Expiry date | Nov 19, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are methods for producing and utilizing T cells comprising chimeric antigen receptors (CAR) comprising a portion of the extracellular domain of a Tumor Necrosis Factor (TNF) superfamily receptor ligand, e.g., A PRoliferation-Inducing Ligand (APRIL). The CAR T cells of this present invention overcome resistance to anti-BCMA targeted therapies and utilize dimerizing and trimerizing transmembrane domains for optimal function. Further, this invention is related to methods of treating cancer, plasma cell diseases or disorders, or autoimmune diseases or disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.